Evidence map›Paper›PMID 31970441›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2020

Resveratrol prevents diabetic nephropathy by reducing chronic inflammation and improving the blood glucose memory effect in non-obese diabetic mice.

Yuxin Xian, Yanyan Gao, Wenshan Lv, Xiaolong Ma, Jianxia Hu, Jingwei Chi, Wei Wang, Yangang Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Modulation of Aging Diseases via RAGE Targets: A Dietary Intervention Review.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuxin XianDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Yanyan GaoDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Wenshan LvDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Xiaolong MaDepartment of Endocrinology, Liaocheng City People's Hospital, Liaocheng, Shandong, China.
Jianxia HuThe Lab of Thyroid Disease, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Jingwei ChiThe Lab of Thyroid Disease, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Wei WangDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China. 18661807392@163.com.
Yangang WangDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.ORCID http://orcid.org/0000-0001-5995-9732
Qingdao University · CNLiaocheng People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic inflammation plays an important role in the development of diabetic nephropathy. Advanced glycation end product receptor (RAGE), nuclear factor kappa B (NF-κB) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (NOX4) are involved in the development of inflammation. Resveratrol is a plant antitoxin; it is believed to have anti-inflammatory effects and can improve blood glucose. We speculate that resveratrol treatment can protect renal function by reducing blood glucose, decreasing the expression of inflammatory factors. Non-obese diabetic (NOD) mice were randomly divided into three groups: T1DM, insulin (INS) and resveratrol (Res) groups. Mice without diabetes were classified as the non-diabetic control group (NOD-C group). The blood glucose (BG) level, blood urea nitrogen (BUN) level, serum creatinine (SCr) level and 24-h urinary microalbumin quantitative (UMA) were measured. The glomerulosclerosis index and basement membrane thickness were calculated under light and electron microscopes. The expression levels of RAGE, NF-кB (P65) and NOX4 in renal tissues were detected by Western blot analysis. We found that resveratrol treatment significantly reduced blood glucose within 28 days of the experiment, but the hypoglycemic effect was not lasting. At the same time, resveratrol reduced BUN, SCr, 24 h UMA and the expression of the inflammatory factors RAGE, NF-кB (P65) and NOX4 and improved the renal pathological structure. We believe that resveratrol improves renal function not only by its anti-inflammatory effect but also by improving the metabolic memory of hyperglycemia.

Indexed as

AnimalsAnti-Inflammatory AgentsAntioxidantsBlood GlucoseDiabetes Mellitus, Type 1Diabetic NephropathiesFemaleInflammationMemory DisordersMiceMice, Inbred NODResveratrolAnti-Inflammatory AgentsAntioxidantsBlood GlucoseResveratrolDiabetic nephropathyMetabolic memory effectResveratrol

Identifiers

PMID31970441
OpenAlexW3002280469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.